NYSE : ANVS
Annovis Bio, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 1.02 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 43.46M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 48.14M |
| Enterprise Value | 29.42M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 16, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 42.61M |
| Shares Outstanding | 42.61M |
| Shares Change (YoY) | +73.71% |
| Shares Change (QoQ) | +34.73% |
| Owned by Insiders (%) | 11.11% |
| Owned by Institutions (%) | 22.11% |
| Float | 37.87M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 3.47 |
| Quick Ratio | 2.95 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -703.68% |
| Return on Assets (ROA) | -142.36% |
| Return on Invested Capital (ROIC) | -439.86% |
| Return on Capital Employed (ROCE) | -315.92% |
| Weighted Average Cost of Capital (WACC) | 11.65% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$7.07M |
| Employee Count | 7 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.35 |
| 52-Week Price Change | -48.64% |
| 50-Day Moving Average | 1.26 |
| 200-Day Moving Average | 1.92 |
| Relative Strength Index (RSI) | 51.67 |
| Average Volume (20 Days) | 718,103 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 5.72M |
| Short Previous Month | 6.02M |
| Short % of Shares Out | 13.43% |
| Short % of Float | 15.11% |
| Short Ratio (days to cover) | 6.83 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -49.53M |
| Pretax Income | -49.52M |
| Net Income | -49.52M |
| EBITDA | n/a |
| EBIT | -49.53M |
| Earnings Per Share (EPS) | -$1.79 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 18.73M |
| Total Debt | n/a |
| Net Cash | 18.73M |
| Net Cash Per Share | $0.44 |
| Equity (Book Value) | -4.25M |
| Book Value Per Share | -0.10 |
| Working Capital | 15.68M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -43.34M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | n/a |
| Net Borrowing | n/a |
| Free Cash Flow | -43.34M |
| FCF Per Share | -$1.02 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -73.71% |
| Shareholder Yield | n/a |
| Earnings Yield | -158.36% |
| FCF Yield | -90.02% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $10.50 |
| Price Target Difference | 829.20% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |